Mostrar el registro sencillo del ítem

dc.contributor.author
Geninatti Crich, S.  
dc.contributor.author
Cadenazzi, M.  
dc.contributor.author
Lanzardo, S.  
dc.contributor.author
Conti, L.  
dc.contributor.author
Ruiu, R.  
dc.contributor.author
Alberti, D.  
dc.contributor.author
Cavallo, F.  
dc.contributor.author
Cutrin, Juan Carlos  
dc.contributor.author
Aime, S.  
dc.date.available
2016-10-31T20:04:16Z  
dc.date.issued
2015-03  
dc.identifier.citation
Geninatti Crich, S.; Cadenazzi, M.; Lanzardo, S.; Conti, L.; Ruiu, R.; et al.; Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells; Taylor & Francis; Nanoscale And Microscale Thermophysical Engineering; 7; 15; 3-2015; 6527-6533  
dc.identifier.issn
1556-7265  
dc.identifier.uri
http://hdl.handle.net/11336/7875  
dc.description.abstract
In this work the selective uptake of native horse spleen ferritin and apoferritin loaded with MRI contrast agents has been assessed in human breast cancer cells (MCF-7 and MDA-MB-231). The higher expression of L-ferritin receptors (SCARA5) led to an enhanced uptake in MCF-7 as shown in T2 and T1 weighted MR images, respectively. The high efficiency of ferritin internalization in MCF-7 has been exploited for the simultaneous delivery of curcumin, a natural therapeutic molecule endowed with antineoplastic and anti-inflammatory action, and the MRI contrast agent Gd-HPDO3A. This theranostic system is able to treat selectively breast cancer cells over-expressing ferritin receptors. By entrapping in apoferritin both Gd-HPDO3A and curcumin, it was possible to deliver a therapeutic dose of 167 μg ml−1 (as calculated by MRI) of this natural drug to MCF-7 cells, thus obtaining a significant reduction of cell proliferation.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Taylor & Francis  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Ferritin  
dc.subject
Theranostic  
dc.subject
Breast Cancer  
dc.subject
Mri  
dc.subject.classification
Otras Nanotecnología  
dc.subject.classification
Nanotecnología  
dc.subject.classification
INGENIERÍAS Y TECNOLOGÍAS  
dc.title
Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2016-08-30T17:11:51Z  
dc.journal.volume
7  
dc.journal.number
15  
dc.journal.pagination
6527-6533  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Geninatti Crich, S.. Universitã â  Di Torino; Italia  
dc.description.fil
Fil: Cadenazzi, M.. Universitã â  Di Torino; Italia  
dc.description.fil
Fil: Lanzardo, S.. Universitã â  Di Torino; Italia  
dc.description.fil
Fil: Conti, L.. Universitã â  Di Torino; Italia  
dc.description.fil
Fil: Ruiu, R.. Universitã â  Di Torino; Italia  
dc.description.fil
Fil: Alberti, D.. Universitã â  Di Torino; Italia  
dc.description.fil
Fil: Cavallo, F.. Universitã â  Di Torino; Italia  
dc.description.fil
Fil: Cutrin, Juan Carlos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas (i); Argentina. Università  Di Torino; Italia  
dc.description.fil
Fil: Aime, S.. Universitã â  Di Torino; Italia  
dc.journal.title
Nanoscale And Microscale Thermophysical Engineering  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://pubs.rsc.org/en/Content/ArticleLanding/2015/NR/C5NR00352K#!divAbstract  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1039/C5NR00352K